AI Engines For more Details: Perplexity Kagi Labs You
Peptic Ulcers: Carbenoxolone is commonly used in the treatment of peptic ulcers, including gastric ulcers and duodenal ulcers. It works by inhibiting the production of gastric acid and promoting the secretion of protective mucus in the stomach lining, which helps to heal ulcers and relieve associated symptoms such as pain and discomfort.
Gastroesophageal Reflux Disease (GERD): Carbenoxolone may also be prescribed to manage symptoms of GERD, a chronic condition characterized by the reflux of stomach acid into the esophagus, leading to heartburn, regurgitation, and other symptoms. By reducing gastric acid secretion, carbenoxolone can help alleviate symptoms and prevent complications associated with GERD.
Inflammatory Bowel Disease (IBD): Some studies suggest that carbenoxolone may have anti-inflammatory properties that could be beneficial in the management of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. However, its use in IBD is less common compared to other medications due to potential side effects and limited efficacy.
Skin Conditions: Carbenoxolone may be used topically to treat certain skin conditions, including eczema, psoriasis, and dermatitis. Its anti-inflammatory properties help reduce redness, itching, and inflammation associated with these conditions, promoting healing and providing symptomatic relief.
Herpes Simplex Infections: Carbenoxolone has been investigated for its potential antiviral effects against herpes simplex virus (HSV) infections, including oral and genital herpes. It may help inhibit viral replication and reduce the severity and duration of herpes outbreaks. However, further research is needed to establish its efficacy and safety in this regard.
Safety Considerations: While generally considered safe when used as directed, carbenoxolone may cause side effects in some individuals, including gastrointestinal disturbances (such as nausea, bloating, and diarrhea), headache, dizziness, and allergic reactions. Long-term use of carbenoxolone may also be associated with adverse effects such as sodium retention, potassium loss, and fluid retention.
Contraindications: Carbenoxolone should be used with caution in individuals with a history of hypertension, heart failure, kidney disease, or electrolyte imbalances, as it may exacerbate these conditions. It is contraindicated in patients with a known hypersensitivity to carbenoxolone or any of its components.
Drug Interactions: Carbenoxolone may interact with certain medications, including corticosteroids, diuretics, and medications that affect electrolyte balance or gastric acidity. It is important to consult with a healthcare professional or pharmacist before using carbenoxolone in combination with other medications.
Pregnancy and Breastfeeding: The safety of carbenoxolone during pregnancy and breastfeeding has not been well established. Pregnant or breastfeeding individuals should consult with a healthcare professional before using this medication to weigh the potential risks and benefits.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 4.6 | 0.9 | 4.11 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 2.1 | 0.57 |
| Allergies | 7.1 | 4.4 | 0.61 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 6 | 5.3 | 0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.7 | 2.71 |
| Ankylosing spondylitis | 3.6 | 1.4 | 1.57 |
| Anorexia Nervosa | 1.6 | 2.7 | -0.69 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 5.3 | 2.5 | 1.12 |
| Atherosclerosis | 1.4 | 1.4 | 0 |
| Atrial fibrillation | 3.5 | 2.2 | 0.59 |
| Autism | 9 | 7.5 | 0.2 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.6 | 2.8 | -3.67 |
| Carcinoma | 4.3 | 2.6 | 0.65 |
| Celiac Disease | 1.4 | 3.8 | -1.71 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 5.1 | 4.9 | 0.04 |
| Chronic Kidney Disease | 4.4 | 1.8 | 1.44 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.7 | 0 |
| Chronic Urticaria (Hives) | 1.6 | 0.5 | 2.2 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 6.5 | 2.5 | 1.6 |
| Constipation | 1.5 | 1.3 | 0.15 |
| Coronary artery disease | 2.5 | 2 | 0.25 |
| COVID-19 | 8.7 | 10.6 | -0.22 |
| Crohn's Disease | 6.3 | 4.4 | 0.43 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.2 | 1.4 | 0.57 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 9.3 | 8.1 | 0.15 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.9 | 2.6 | -0.37 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.8 | 1.4 | 1 |
| erectile dysfunction | 2.2 | 0.3 | 6.33 |
| Fibromyalgia | 3.1 | 1.6 | 0.94 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 3.4 | 0.41 |
| gallstone disease (gsd) | 3.3 | 0.9 | 2.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1.2 | -2 |
| Generalized anxiety disorder | 2.7 | 2.6 | 0.04 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.5 | 1.2 | 1.08 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 0.6 | 0.5 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.6 | 1.2 | 1.17 |
| Heart Failure | 4 | 1.4 | 1.86 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.6 | 0.6 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.1 | 6 |
| hyperglycemia | 2.6 | 1.4 | 0.86 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.7 | 4.8 | -0.3 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 3.3 | 0.6 | 4.5 |
| IgA nephropathy (IgAN) | 1.6 | 3.7 | -1.31 |
| Inflammatory Bowel Disease | 7.9 | 7.5 | 0.05 |
| Insomnia | 2.8 | 2.6 | 0.08 |
| Intelligence | 1 | 0.3 | 2.33 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 6.3 | 4.4 | 0.43 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 7.3 | 4.4 | 0.66 |
| Long COVID | 6.5 | 7.7 | -0.18 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.2 | 0.25 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.9 | 2.3 | -1.56 |
| ME/CFS without IBS | 1.9 | 1.8 | 0.06 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.6 | 2.5 |
| Metabolic Syndrome | 7.3 | 6.4 | 0.14 |
| Mood Disorders | 9.8 | 6.9 | 0.42 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 6.6 | 4.7 | 0.4 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3 | -9 |
| Neuropathy (all types) | 0.8 | 2.8 | -2.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.5 | 4.5 | 0.22 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 10.1 | 7.7 | 0.31 |
| obsessive-compulsive disorder | 4.9 | 3.4 | 0.44 |
| Osteoarthritis | 2.6 | 1.2 | 1.17 |
| Osteoporosis | 2.8 | 1.7 | 0.65 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 8.2 | 5.7 | 0.44 |
| Polycystic ovary syndrome | 5.2 | 3.3 | 0.58 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 2.1 | 2.5 | -0.19 |
| Psoriasis | 3.1 | 2.1 | 0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.1 | 3.3 | 1.45 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 7.1 | 3.1 | 1.29 |
| scoliosis | 0.5 | 0.9 | -0.8 |
| Sjögren syndrome | 2.9 | 2.6 | 0.12 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 2.6 | 2.9 | -0.12 |
| Systemic Lupus Erythematosus | 3.9 | 2.1 | 0.86 |
| Tic Disorder | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.2 | 3.8 | 0.11 |
| Type 2 Diabetes | 7.6 | 5.8 | 0.31 |
| Ulcerative colitis | 5.5 | 5.2 | 0.06 |
| Unhealthy Ageing | 3.9 | 2 | 0.95 |
| Vitiligo | 1.9 | 1.5 | 0.27 |
